Geron Past Earnings Performance

Past criteria checks 0/6

Geron's earnings have been declining at an average annual rate of -29.7%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 0.4% per year.

Key information

-29.7%

Earnings growth rate

-8.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-0.4%
Return on equity-74.3%
Net Margin-77,690.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25
Is Geron (NASDAQ:GERN) A Risky Investment?

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

May 12
Is Geron (NASDAQ:GERN) Using Debt Sensibly?

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20
An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14
Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05
Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Geron: Waiting For Godot

Jul 15

Geron: TLR Is 10 Months Away

May 03

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Feb 25
Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron: Just One More Year Of Patience, Then Decision Time

Feb 23

With No Catalysts At ASH, Geron Corp. Remains In A Holding Pattern

Nov 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Nov 04
Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Geron: Still A Strong Buy After New Phase II Data And 20% Return

Oct 22

Revenue & Expenses Breakdown
Beta

How Geron makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:GERN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-184700
30 Sep 230-175700
30 Jun 230-171600
31 Mar 230-150510
31 Dec 221-142450
30 Sep 222-131320
30 Jun 221-117300
31 Mar 221-118300
31 Dec 211-116310
30 Sep 210-108300
30 Jun 210-101300
31 Mar 210-8728-4
31 Dec 200-76270
30 Sep 200-81250
30 Jun 200-76230
31 Mar 200-75222
31 Dec 190-69220
30 Sep 191-47211
30 Jun 191-37202
31 Mar 191-30195
31 Dec 181-27190
30 Sep 181-27193
30 Jun 181-28202
31 Mar 181-28202
31 Dec 171-28193
30 Sep 171-29193
30 Jun 176-26183
31 Mar 176-28193
31 Dec 166-30193
30 Sep 166-30194
30 Jun 16371195
31 Mar 16371186
31 Dec 15360188
30 Sep 153601810
30 Jun 151-371711
31 Mar 151-371712
31 Dec 141-361712
30 Sep 141-361612
30 Jun 141-351512
31 Mar 141-351512
31 Dec 131-381614
30 Sep 132-451618
30 Jun 132-531821
31 Mar 132-622024

Quality Earnings: GERN is currently unprofitable.

Growing Profit Margin: GERN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.

Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: GERN has a negative Return on Equity (-74.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.